52995 Dupilumab for the treatment of dermatologic adverse events associated with MEK and EGFR inhibitors
Year: 2024
Type: article
Study design: Observational Study
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4402104491
